Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 739 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Calverton, MarylandAges 18 years+ - NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07292246Recruiting
HandX-assisted endoscopic mastectomy study for breast cancer
This trial tests a new, less invasive way to remove breast tissue using a small camera (endoscope) with a device called HandX. It's for women who need a mastectomy for early-stage breast cancer, DCIS, or to reduce high risk, and aims to see if it's safe and works well.
Glyfada, AtticaAges 18 years+ - NCT07451912RecruitingPhase 1/Phase 2
Venetoclax Combo for CEBPA-Mutated AML in Unfit Patients
This trial tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) for people with newly diagnosed AML that has a CEBPA gene mutation and who are not strong enough for standard intensive chemotherapy. The goal is to see if this gentler approach works well.
Suzhou, JiangsuAges 18 years+ - NCT07563205Recruiting
Study of Chemotherapy and Amivantamab for Advanced Lung Cancer
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Aix-en-ProvenceAges 18 years+ - NCT06789913RecruitingPhase 2
Testing RLY-2608 for growth disorders linked to PIK3CA mutations
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
Phoenix, ArizonaAges 2 years+ - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT07668752RecruitingPhase 3
New pill (GFH375) vs chemo for KRAS G12D lung cancer
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07286292RecruitingPhase 2
Vorasidenib for children with IDH-mutated low-grade glioma
This trial studies an oral drug called vorasidenib for children and teens with a slow-growing brain tumor (Grade 2 astrocytoma or oligodendroglioma) that has an IDH1 or IDH2 mutation. The drug is taken daily and may help keep the tumor from growing, avoiding the need for immediate chemotherapy or radiation.
SydneyAges 12–17 - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT06585800Enrolling by invitation
Studying gene changes in tissues
This study looks at genetic changes that occur naturally in human tissues. If you are already scheduled for surgery or a procedure like a biopsy or endoscopy, researchers may ask for a small tissue sample to study how our cells can change over time.
CambridgeAges 18 years+ - NCT06357845Recruiting
East Palestine chemical exposure and genetic change study
This study looks at whether the chemical spill in East Palestine in 2023 caused changes in people's genes. It involves giving a blood or saliva sample to measure any tiny genetic changes linked to the exposure. It helps researchers understand long-term health risks.
Cleveland, OhioAges 18 years+ - NCT07006688RecruitingPhase 1
Ivosidenib for IDH1-mutated cancers with liver or kidney issues
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
Atlanta, GeorgiaAges 18 years+ - NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06851052Enrolling by invitation
How do DNA changes happen in health and disease?
This study is looking at DNA changes (mutations) in healthy people and in people who may have DNA damage from things like the sun, smoking, past diseases, or treatments like radiation. The goal is to better understand how these changes happen and what they mean.
CambridgeAges 18 years+ - NCT06678685RecruitingPhase 2/Phase 3
Spironolactone for children with NCOR gene changes and autism
This trial tests if spironolactone can help children with autism who have a certain genetic change (in the NCOR gene). The study will monitor improvement and safety over time.
Jinan, ShandongAges 3–10 - NCT06667544RecruitingPhase 1/Phase 2
Study of RNK08954 for advanced cancers with KRAS G12D mutation
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
Nanning, GuangxiAges 18 years+ - NCT06611839RecruitingPhase 1/Phase 2
Combination therapy for IDH1-mutated AML
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06548919Recruiting
Treatment patterns for ESR1-mutated advanced breast cancer
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Suzhou, JiangsuAges 18 years+ - NCT05858983RecruitingPhase 1/Phase 2
Gene therapy for certain RPE65 inherited eye conditions
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
Beijing, Beijing MunicipalityAges 8–45 - NCT05236946RecruitingPhase 3
Brain radiation timing study for gene-mutated lung cancer
This study compares giving brain radiation right away versus waiting, in people with lung cancer that has an EGFR or ALK gene change and has spread to the brain but causes no symptoms. It aims to see which approach helps control the brain cancer better and keeps quality of life stable.
Mumbai, MaharashtraAges 18–99 - NCT05024552RecruitingPhase 1
Vyxeos plus gilteritinib for certain relapsed AML
This Phase 1 trial studies whether combining Vyxeos (a chemotherapy) with gilteritinib (a targeted drug) can treat AML that has come back or hasn’t responded well, specifically AML with certain FLT3 mutations. If it works, it could improve chances of controlling the leukemia.
Tampa, FloridaAges 18 years+ - NCT04144569RecruitingPhase 2
PD-1 plus pyrotinib for HER2-mutated lung cancer after chemo
This trial tests a combination treatment—PD-1 plus pyrotinib—in people with advanced lung cancer that has a specific HER2 “insertion” genetic change. It may help if your first standard chemotherapy did not work and you still have measurable tumors to track.
Changsha, HunanAges 18–75
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 739 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.